Gain Therapeutics, Inc. announced a private placement of 2,500,088 shares of common stock at a price of $2 per share and pre funded warrants at a price of $2 per share for the gross proceeds of $5,000,176 on November 20, 2023. The warrants will be exercisable into 2,500,088 shares of common stock at an exercise price of $2.75 per share. The transaction is expected to close on November 24, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.42 USD | -1.22% | -7.98% | -25.88% |
04-24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
04-08 | Gain Therapeutics Names Gene Mack as CFO | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.88% | 44.23M | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- Gain Therapeutics, Inc. announced that it expects to receive $5.000176 million in funding